-
Mashup Score: 20Access barriers to anti-CD19+ CART therapy for NHL across a community transplant and cellular therapy network - 2 day(s) ago
Key pointsForty-one percent of referrals in the community were unable to access anti-CD19+ CARTs for NHL between 2018 and 2022.Attrition from disease-relat
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
#Hematology Access barriers to anti-CD19+ #CARTcell therapy for #NHL #lymphoma across a community transplant and cellular therapy network #lymsm https://t.co/ilxu6SZ8UA